Cargando…

Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study

The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Toyohiro, Nakane, Keita, Enomoto, Torai, Tomioka, Masayuki, Taniguchi, Tomoki, Ishida, Takashi, Ozawa, Kaori, Takagi, Kimiaki, Ito, Hiroki, Takeuchi, Shinichi, Kawase, Makoto, Kawase, Kota, Kato, Daiki, Takai, Manabu, Iinuma, Koji, Yokoi, Shigeaki, Nakano, Masahiro, Koie, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/
https://www.ncbi.nlm.nih.gov/pubmed/36140344
http://dx.doi.org/10.3390/biomedicines10092243
_version_ 1784794244028825600
author Yamada, Toyohiro
Nakane, Keita
Enomoto, Torai
Tomioka, Masayuki
Taniguchi, Tomoki
Ishida, Takashi
Ozawa, Kaori
Takagi, Kimiaki
Ito, Hiroki
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Kato, Daiki
Takai, Manabu
Iinuma, Koji
Yokoi, Shigeaki
Nakano, Masahiro
Koie, Takuya
author_facet Yamada, Toyohiro
Nakane, Keita
Enomoto, Torai
Tomioka, Masayuki
Taniguchi, Tomoki
Ishida, Takashi
Ozawa, Kaori
Takagi, Kimiaki
Ito, Hiroki
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Kato, Daiki
Takai, Manabu
Iinuma, Koji
Yokoi, Shigeaki
Nakano, Masahiro
Koie, Takuya
author_sort Yamada, Toyohiro
collection PubMed
description The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and the BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p < 0.001). The median progression-free survival (PFS) times were 4 months in the BSC group and 14 months in the treatment group (p < 0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. Third-line therapy may have clinical potential advantages for improving the oncological outcomes in patients with mUC.
format Online
Article
Text
id pubmed-9496337
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94963372022-09-23 Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study Yamada, Toyohiro Nakane, Keita Enomoto, Torai Tomioka, Masayuki Taniguchi, Tomoki Ishida, Takashi Ozawa, Kaori Takagi, Kimiaki Ito, Hiroki Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Kato, Daiki Takai, Manabu Iinuma, Koji Yokoi, Shigeaki Nakano, Masahiro Koie, Takuya Biomedicines Article The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and the BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p < 0.001). The median progression-free survival (PFS) times were 4 months in the BSC group and 14 months in the treatment group (p < 0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. Third-line therapy may have clinical potential advantages for improving the oncological outcomes in patients with mUC. MDPI 2022-09-09 /pmc/articles/PMC9496337/ /pubmed/36140344 http://dx.doi.org/10.3390/biomedicines10092243 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yamada, Toyohiro
Nakane, Keita
Enomoto, Torai
Tomioka, Masayuki
Taniguchi, Tomoki
Ishida, Takashi
Ozawa, Kaori
Takagi, Kimiaki
Ito, Hiroki
Takeuchi, Shinichi
Kawase, Makoto
Kawase, Kota
Kato, Daiki
Takai, Manabu
Iinuma, Koji
Yokoi, Shigeaki
Nakano, Masahiro
Koie, Takuya
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title_full Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title_fullStr Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title_full_unstemmed Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title_short Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
title_sort oncological outcomes in patients with metastatic urothelial carcinoma after discontinuing pembrolizumab as a second-line treatment: a retrospective multicenter real-world cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/
https://www.ncbi.nlm.nih.gov/pubmed/36140344
http://dx.doi.org/10.3390/biomedicines10092243
work_keys_str_mv AT yamadatoyohiro oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT nakanekeita oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT enomototorai oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT tomiokamasayuki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT taniguchitomoki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT ishidatakashi oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT ozawakaori oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT takagikimiaki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT itohiroki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT takeuchishinichi oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT kawasemakoto oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT kawasekota oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT katodaiki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT takaimanabu oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT iinumakoji oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT yokoishigeaki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT nakanomasahiro oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy
AT koietakuya oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy